Levofloxacin Corneal Penetration and Clinical Implications

Clinical Efficacy and Dosage

The American Academy of Ophthalmology recommends levofloxacin 1.5% for bacterial keratitis treatment, demonstrating equal efficacy to ofloxacin 0.3% in achieving complete re-epithelialization, with a higher concentration providing potentially greater corneal penetration 1
For central or severe keratitis with deep stromal involvement or infiltrates >2 mm, a loading dose every 5-15 minutes followed by hourly applications is recommended to maximize tissue concentrations, according to the American Academy of Ophthalmology 1
The enhanced corneal penetration of levofloxacin makes it particularly suitable for monotherapy in bacterial keratitis, as suggested by the American Academy of Ophthalmology 1

The American Academy of Ophthalmology notes that fluoroquinolones, including levofloxacin, are generally poorly effective against methicillin-resistant Staphylococcus aureus (MRSA), which shows 42% prevalence in staphylococcal isolates 2
Increasing resistance to fluoroquinolones has been documented, particularly in patients with recent fluoroquinolone use, hospitalization, or recent ocular surgery, as reported by the American Academy of Ophthalmology 2

While levofloxacin demonstrates superior penetration compared to earlier fluoroquinolones, fourth-generation agents (moxifloxacin, gatifloxacin) have better gram-positive coverage, though they are not FDA-approved for bacterial keratitis, according to the American Academy of Ophthalmology 2
An in vitro study showed no empiric coverage advantage of moxifloxacin over several organisms, as noted by the American Academy of Ophthalmology 2